Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study

Bodnar, Lubomir; Wcisło, Gabriel; Gąsowska-Bodnar, Agnieszka; Synowiec, Agnieszka; Szarlej-Wcislo, Katarzyna; Szczylik, Cezary

doi:10.1016/j.ejca.2008.08.005

Cited by 95 publications

(72 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although detailed tissue types were not considered in the present study, the results regarding increases in PTH or PTH-rP levels in patients with ESCC may be associated with this specificity. However, previous studies reported that Mg supplementation did not affect the tumor response to cisplatin-based chemotherapy (9,11,25). It was also concluded in the present study that Mg supplementation did not affect the efficacy of cisplatin-containing chemotherapy, as the overall survival time was similar between the patients with or without Mg supplementation (Fig.…”

Section: Discussionsupporting

confidence: 48%

“…1 and Table II). The protective effects of oral or intravenous Mg supplementation against cisplatin-induced nephrotoxicity have been reported in various types of malignancy, including in lung (10-12), head and neck (10,23,24), digestive (8,10), testicular (25), ovarian (9,24) and bladder (24) cancer. However, just a limited number of clinical reports have demonstrated the protective effects of intravenous Mg supplementation against cisplatin-induced nephrotoxicity in ESCC (10).…”

Section: Discussionmentioning

confidence: 99%

“…This Mg depletion has been demonstrated to further enhance renal platinum accumulation and cisplatin-induced nephrotoxicity. Therefore, oral or intravenous Mg supplementation can confer renal protective effects against cisplatin-induced nephrotoxicity (8)(9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Magnesium (Mg) supplementation has previously been demonstrated to confer protective effects against nephrotoxicity induced by cisplatin. Parathyroid hormone (PTH) regulates Mg homeostasis. The aim of present study was to determine the protective effects of Mg supplementation against cisplatin-induced nephrotoxicity and its association with PTH levels in patients with esophageal squamous cell carcinoma (ESCC). A total of 55 patients with primary ESCC who received chemotherapy with high-dose cisplatin were examined. Mg was administered intravenously, and serum concentrations of PTH, parathyroid hormone-related protein (PTH-rP), creatinine and Mg were prospectively measured. Of the 55 patients, 37 received Mg supplementation. Post-chemotherapeutic creatinine concentrations were significantly increased in patients without Mg supplementation (P=0.01), with grade 1 and 2 increases of 22.2 and 5.6%, respectively, whereas these increases were suppressed by Mg supplementation (change in creatinine, P=0.21), with grade 1 and 2 increases of 8.1 and 0%, respectively. In addition, PTH and PTH-rP concentrations were high in 8 (14.5%) and 6 (10.9%) of all 55 patients, respectively. Alterations in creatinine concentrations (post-/pre-chemotherapy) due to chemotherapy were higher in patients with high levels of PTH regardless of Mg supplementation (P<0.01). Pre-therapeutic creatinine concentrations did not correlate with the alterations in creatinine concentrations due to chemotherapy. Intravenous Mg supplementation therefore conferred protective effects against cisplatin-induced nephrotoxicity in patients with ESCC. Furthermore, increases in PTH or PTH-rP may have influenced the extent of nephrotoxicity.

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The value was comparable with those in previous reports (28,29). Furthermore, the protective effect of magnesium supplementation and the preventive effect of magnesium preloading on nephrotoxicity in cancer patients receiving CDDP-based chemotherapy have been reported (30,31); therefore, the underlying mechanisms may become clearer through examination of the effect of Fe, released by CDDP treatment, on serum and tissue magnesium levels.…”

Section: Discussionmentioning

confidence: 99%

Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy

Nakamura¹,

Takahashi²,

Niigata³

et al. 2016

Biomedical Reports

View full text Add to dashboard Cite

Abstract. The administration of cisplatin (CDDP) may influence trace metal concentrations in body fluids. In order to test this hypothesis, the blood concentrations of trace metals were determined during the present study in eight Japanese esophageal and lung cancer patients receiving CDDP-based chemotherapy. The levels of manganese, iron (Fe), cobalt, copper, zinc (Zn), platinum and lead in the plasma were determined by inductively coupled plasma-mass spectrometry. In addition, the serum levels of Fe, transferrin and ferritin were evaluated. The baseline plasma concentration of Fe in patients with esophageal cancer was significantly lower than that in lung cancer patients (P=0.011), although there were no significant differences identified with respect to the plasma levels of other trace metals. The data obtained from six fasting patients without blood transfusion demonstrated that plasma concentrations of Fe increased 3.5-fold soon after CDDP treatment and returned to baseline levels ~10 days after therapy. The excessive Fe levels in the bloodstream induced changes in serum ferritin and transferrin levels. Furthermore, serum Zn levels increased 1.8-fold in the 1-3 days following CDDP treatment, and serum cystatin C levels transiently increased. These findings indicate that serum Fe and Zn levels may be useful to understanding the physiological responses in the early stages of CDDP-based chemotherapy, which may be associated with systemic inflammation and/or tissue distribution of CDDP.

show abstract

“…The cisplatin challenge is known to hinder tubular reabsorption, resulting in a concentration defect and disturbance of the renal handling of electrolytes. Several studies have indicated the association of cisplatin toxicity with the depletion of serum magnesium, and magnesium supplementation was adopted to prevent hypomagnesemia during drug treatment (27). Hypomagnesemia was observed in humans (28) and in experimental animals (29).…”

Section: Discussionmentioning

confidence: 99%

Changes in the serum, liver, and renal cortical lipids and electrolytesin rabbits with cisplatin-induced nephrotoxicity

Abdel-Gayoum¹,

Ahmida²

2017

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Cisplatin is an anticancer drug that can induce nephrotoxicity. Its toxicity is associated with dyslipidemia and disturbed electrolyte balance. In the present study we investigated the changes in serum lipid profile and electrolyte levels and their contents in kidney and liver tissues of rabbits treated with cisplatin.Materials and methods: Twenty-eight adult male New Zealand White rabbits were used in the experiment. Animals of groups C, P1, and P2 were injected with saline, cisplatin (4.0 mg/kg bw), and cisplatin (6.5 mg/kg bw), respectively, and killed 3 days after the injections. Animals of group R were given cisplatin (6.5 mg/kg bw) and killed after 7 days. All animals were killed after an overnight fast. Results:The P2 animals showed reductions in their body weights, significant (P < 0.001) increases in serum creatinine and urea levels, and significant (P < 0.001) drops in cortical alkaline phosphatase activity and necrotic kidney histology. The treatments had no effect on liver function. Moreover, the P2 animals showed increased serum cholesterol, TAG, and elevated LDL-cholesterol, with significant accumulations of the kidney cholesterol and TAG, but no change in serum phospholipid and depleted hepatic cholesterol. Moreover, the P2 animals had depressed serum levels of potassium, calcium, and magnesium, and reduced renal cortical calcium and magnesium contents and depressed liver calcium but not magnesium. However, the P1 animals had no significant alterations in their lipid or electrolyte levels. Most of the perturbed parameters returned to normal levels in the recovery group. Conclusion:Cisplatin nephrotoxicity in rabbits is accompanied by reductions in body weight, secondary dyslipidemia, and reduced serum potassium, calcium, and magnesium with depleted renal cortical magnesium and calcium and accumulated cortical lipids.

show abstract

Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study

Cited by 95 publications

References 24 publications

Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma

Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma

Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy

Changes in the serum, liver, and renal cortical lipids and electrolytesin rabbits with cisplatin-induced nephrotoxicity

Contact Info

Product

Resources

About